Compare DNUT & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | VOGX |
|---|---|---|
| Founded | 1937 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.8M | 482.8M |
| IPO Year | 2021 | 2026 |
| Metric | DNUT | VOGX |
|---|---|---|
| Price | $2.91 | $20.63 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $4.08 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 103.4K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,522,616,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.87 | $14.80 |
| 52 Week High | $5.11 | $38.41 |
| Indicator | DNUT | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 30.91 | 45.30 |
| Support Level | N/A | $20.64 |
| Resistance Level | $3.69 | $36.96 |
| Average True Range (ATR) | 0.08 | 3.23 |
| MACD | -0.02 | -1.33 |
| Stochastic Oscillator | 3.57 | 12.89 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.